PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis
USA - NYSEARCA:PLX - US74365A3095 - Common Stock
2.265 USD
-0.11 (-4.83%)
Taking everything into account, PLX scores 5 out of 10 in our fundamental rating. PLX was compared to 534 industry peers in the Biotechnology industry. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here. PLX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year PLX was profitable.
PLX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
PLX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.00%, PLX belongs to the top of the industry, outperforming 93.07% of the companies in the same industry.
The Return On Equity of PLX (12.57%) is better than 93.82% of its industry peers.
The Return On Invested Capital of PLX (12.68%) is better than 94.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROIC | 12.68% |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PLX has a Profit Margin of 10.13%. This is amongst the best in the industry. PLX outperforms 92.13% of its industry peers.
PLX's Operating Margin of 13.28% is amongst the best of the industry. PLX outperforms 93.07% of its industry peers.
With a decent Gross Margin value of 57.53%, PLX is doing good in the industry, outperforming 77.72% of the companies in the same industry.
In the last couple of years the Gross Margin of PLX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PLX is still creating some value.
PLX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PLX has more shares outstanding
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PLX has an Altman-Z score of -1.06. This is a bad value and indicates that PLX is not financially healthy and even has some risk of bankruptcy.
PLX has a Altman-Z score (-1.06) which is in line with its industry peers.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.06 |
ROIC/WACC1.42
WACC8.94%
2.3 Liquidity
A Current Ratio of 2.72 indicates that PLX has no problem at all paying its short term obligations.
PLX has a worse Current ratio (2.72) than 67.23% of its industry peers.
A Quick Ratio of 1.84 indicates that PLX should not have too much problems paying its short term obligations.
The Quick ratio of PLX (1.84) is worse than 76.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 135.00% over the past year.
Looking at the last year, PLX shows a very strong growth in Revenue. The Revenue has grown by 62.79%.
The Revenue has been decreasing by -0.48% on average over the past years.
EPS 1Y (TTM)135%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)62.79%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%16.21%
3.2 Future
PLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 238.30% yearly.
PLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.15% yearly.
EPS Next Y337.67%
EPS Next 2Y328.35%
EPS Next 3Y238.3%
EPS Next 5YN/A
Revenue Next Year12.26%
Revenue Next 2Y40.47%
Revenue Next 3Y44.15%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 32.36 indicates a quite expensive valuation of PLX.
Compared to the rest of the industry, the Price/Earnings ratio of PLX indicates a rather cheap valuation: PLX is cheaper than 92.70% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.13, PLX is valued a bit more expensive.
Based on the Price/Forward Earnings ratio of 4.11, the valuation of PLX can be described as very cheap.
PLX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PLX is cheaper than 99.25% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.35, PLX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.36 | ||
| Fwd PE | 4.11 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PLX indicates a rather cheap valuation: PLX is cheaper than 94.76% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 14.68 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PLX's earnings are expected to grow with 238.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.1
PEG (5Y)N/A
EPS Next 2Y328.35%
EPS Next 3Y238.3%
5. Dividend
5.1 Amount
PLX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:PLX (11/6/2025, 12:38:13 PM)
2.265
-0.11 (-4.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.15%
Inst Owner Change-0.43%
Ins Owners3.5%
Ins Owner Change0%
Market Cap180.59M
Revenue(TTM)61.95M
Net Income(TTM)6.28M
Analysts80
Price Target14.28 (530.46%)
Short Float %6.57%
Short Ratio5.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.51%
Min EPS beat(2)-265.02%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-90.87%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)2
Avg EPS beat(8)-112.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.6%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)14.45%
Revenue beat(4)2
Avg Revenue beat(4)-8.41%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)5
Avg Revenue beat(8)3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-58.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.36 | ||
| Fwd PE | 4.11 | ||
| P/S | 2.92 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.62 | ||
| P/tB | 3.62 | ||
| EV/EBITDA | 14.68 |
EPS(TTM)0.07
EY3.09%
EPS(NY)0.55
Fwd EY24.3%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.78
BVpS0.63
TBVpS0.63
PEG (NY)0.1
PEG (5Y)N/A
Graham Number0.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8% | ||
| ROE | 12.57% | ||
| ROCE | 15.12% | ||
| ROIC | 12.68% | ||
| ROICexc | 32.84% | ||
| ROICexgc | 32.84% | ||
| OM | 13.28% | ||
| PM (TTM) | 10.13% | ||
| GM | 57.53% | ||
| FCFM | N/A |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 91.23% | ||
| Cap/Sales | 2.02% | ||
| Interest Coverage | 10.74 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 1.84 | ||
| Altman-Z | -1.06 |
F-Score6
WACC8.94%
ROIC/WACC1.42
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y337.67%
EPS Next 2Y328.35%
EPS Next 3Y238.3%
EPS Next 5YN/A
Revenue 1Y (TTM)62.79%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%16.21%
Revenue Next Year12.26%
Revenue Next 2Y40.47%
Revenue Next 3Y44.15%
Revenue Next 5YN/A
EBIT growth 1Y155.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.67%
OCF growth 3YN/A
OCF growth 5YN/A
PROTALIX BIOTHERAPEUTICS INC / PLX FAQ
What is the ChartMill fundamental rating of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PLX.
What is the valuation status of PROTALIX BIOTHERAPEUTICS INC (PLX) stock?
ChartMill assigns a valuation rating of 6 / 10 to PROTALIX BIOTHERAPEUTICS INC (PLX). This can be considered as Fairly Valued.
What is the profitability of PLX stock?
PROTALIX BIOTHERAPEUTICS INC (PLX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for PLX stock?
The Price/Earnings (PE) ratio for PROTALIX BIOTHERAPEUTICS INC (PLX) is 32.36 and the Price/Book (PB) ratio is 3.62.
Can you provide the expected EPS growth for PLX stock?
The Earnings per Share (EPS) of PROTALIX BIOTHERAPEUTICS INC (PLX) is expected to grow by 337.67% in the next year.